Fungicidal activity of five cathelicidin peptides against clinically isolated yeasts

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 950-959

  Benincasa, Monica ^a   Scocchi, Marco ^a   Pacor, Sabrina ^a   Tossi, Alessandro ^a   Nobili, Donatella ^a   Basaglia, Giancarlo ^b   Busetti, Marina ^a   Gennaro, Renato ^a  

^a UNIVERSITY OF TRIESTE   (Italy)

^b CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Antifungals; Cathelicidin; Clinical isolates; Host defence; Immunocompromised patients; Innate immunity; Pathogenic fungi

Indexed keywords

ANTIFUNGAL AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE BINDING PROTEIN; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CATTLE; CELL MEMBRANE PERMEABILITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG EFFECT; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MOLECULAR GENETICS; SWINE;

AMINO ACID SEQUENCE; ANIMALS; ANTIFUNGAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CANDIDA ALBICANS; CANDIDIASIS; CATTLE; CELL MEMBRANE PERMEABILITY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; SWINE;

EID: 39049135214     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl382     Document Type: Article

References (44)

1. Venkatesan P, Perfect JR, Myers SA. Evaluation and management of fungal infections in immunocompromised patients. Dermatol Ther 2005; 18: 44-57.
2. Ostrosky-Zeichner L, Rex JH, Bennett J et al. Deeply invasive candidiasis. Infect Dis Clin North Am 2002; 16: 821-35.
3. Prasad R, Kapoor K. Multidrug resistance in yeast Candida. Int Rev Cytol 2005; 242: 215-48.
4. Perea S, Patterson TF. Antifungal resistance in pathogenic fungi. Clin Infect Dis 2002; 35: 1073-80.
5. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2002; 14: 96-102.
6. Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J Leukoc Biol 2004; 75: 39-48.
7. Gennaro R, Zanetti M. Structural features and biological activities of the cathelicidin-derived antimicrobial peptides. Biopolymers 2000; 55: 31-49.
8. Benincasa M, Skerlavaj B, Gennaro R et al. In vitro and in vivo antimicrobial activity of two α-helical cathelicidin peptides and of their synthetic analogs. Peptides 2003; 24: 1723-31.
9. Brogden KA, Kalfa VC, Ackermann MR et al. The ovine cathelicidin SMAP29 kills ovine respiratory pathogens in vitro and in an ovine model of pulmonary infection. Antimicrob Agents Chemother 2001; 45: 331-4.
10. Giacometti A, Cirioni O, Ghiselli R et al. The antimicrobial peptide BMAP-28 reduces lethality in mouse models of staphylococcal sepsis. Crit Care Med 2004; 32: 2485-90.
11. Giacometti A, Cirioni O, Ghiselli R et al. Cathelicidin peptide sheep myeloid antimicrobial peptide-29 prevents endotoxin-induced mortality in rat models of septic shock. Am J Respir Crit Care Med 2004; 169: 187-94.
12. Skerlavaj B, Benincasa M, Risso A et al. SMAP-29: A potent antibacterial and antifungal peptide from sheep leukocytes. FEBS Lett 1999; 463: 58-62.
13. Skerlavaj B, Gennaro R, Bagella L et al. Biological characterization of two novel cathelicidin-derived peptides and identification of structural requirements for their antimicrobial and cell lytic activities. J Biol Chem 1996; 271: 28375-81.
14. Brogden KA. Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 2005; 3: 238-50.
15. Chan DI, Prenner EJ, Vogel HJ. Tryptophan- and arginine-rich antimicrobial peptides: Structures and mechanisms of action. Biochim Biophys Acta 2006, in press.
16. Lee DG, Kim HK, Kim SA et al. Fungicidal effect of indolicidin and its interaction with phospholipid membranes. Biochem Biophys Res Commun 2003; 305: 305-10.
17. Aumelas A, Mangoni M, Roumestand C et al. Synthesis and solution structure of the antimicrobial peptide protegrin-1. Eur J Biochem 1996; 237: 575-83.
18. Buffy JJ, Waring AJ, Lehrer RI et al. Immobilization and aggregation of the antimicrobial peptide protegrin-1 in lipid bilayers investigated by solid-state NMR. Biochemistry 2003; 42: 13725-34.
19. Cho Y, Turner JS, Dinh NN et al. Activity of protegrins against yeast-phase Candida albicans. Infect Immun 1998; 66: 2486-93.
20. Chen J, Falla TJ, Liu H et al. Development of protegrins for the treatment and prevention of oral mucositis: Structure-activity relationships of synthetic protegrin analogues. Biopolymers 2000; 55: 88-98.
21. Giles FJ, Rodriguez R, Weisdorf D et al. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy. Leuk Res 2004; 28: 559-65.
22. Putsep K, Carlsson G, Boman HG et al. Deficiency of antibacterial peptides in patients with morbus Kostmann: An observation study. Lancet 2002; 360: 1144-9.
23. Brodsky IE, Ghori N, Falkow S et al. Mig-14 is an inner membrane-associated protein that promotes Salmonella typhimurium resistance to CRAMP, survival within activated macrophages and persistent infection. Mol Microbiol 2005; 55: 954-72.
24. Rodriguez-Tudela JL, Berenguer J, Martinez-Suarez JV et al. Comparison of a spectrophotometric microdilution method with RPMI-2% glucose with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro susceptibility testing of amphotericin B, flucytosine, and fluconazole against Candida albicans. Antimicrob Agents Chemother 1996; 40: 1998-2003.
25. Koshlukova SE, Lloyd TL, Araujo MW et al. Salivary histatin 5 induces non-lytic release of ATP from Candida albicans leading to cell death. J Biol Chem 1999; 274: 18872-9.
26. Kwon-Chung K. Gene disruption to evaluate the role of fungal candidate virulence genes. Curr Opin Microbiol 1998; 1: 381-9.
27. Kozel TR, Pfrommer GS, Guerlain AS et al. Role of the capsule in phagocytosis of Cryptococcus neoformans. Rev Infect Dis 1988; 10 Suppl 2: S436-9.
28. Tiozzo E, Rocco G, Tossi A et al. Wide-spectrum antibiotic activity of synthetic, amphipathic peptides. Biochem Biophys Res Commun 1998; 249: 202-6.
29. Giangaspero A, Sandri L, Tossi A. Amphipathic α-helical antimicrobial peptides. Eur J Biochem 2001; 268: 5589-600.
30. Canton E, Peman J, Gobernado M et al. Patterns of amphotericin B killing kinetics against seven Candida species. Antimicrob Agents Chemother 2004; 48: 2477-82.
31. Burgess DS, Hastings RW. A comparison of dynamic characteristics of fluconazole, itraconazole, and amphotericin B against Cryptococcus neoformans using time-kill methodology. Diagn Microbiol Infect Dis 2000; 38: 87-93.
32. Roling EE, Klepser ME, Wasson A et al. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagn Microbiol Infect Dis 2002; 43: 13-17.
33. Pina-Vaz C, Sansonetty F, Rodrigues AG et al. Cytometric approach for a rapid evaluation of susceptibility of Candida strains to antifungals. Clin Microbiol Infect 2001; 7: 609-18.
34. Nosanchuk JD, Cleare W, Franzot SP et al. Amphotericin B and fluconazole affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob Agents Chemother 1999; 43: 233-9.
35. White TC, Marr KA, Bowden RA. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998; 11: 382-402.
36. Wingard JR, Merz WG, Rinaldi MG et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991; 325: 1274-7.
37. Lopez-Garcia B, Lee PH, Yamasaki K et al. Anti-fungal activity of cathelicidins and their potential role in Candida albicans skin infection. J Invest Dermatol 2005; 125: 108-115.
38. Morassutti C, De Amicis F, Bandiera A et al. Expression of SMAP-29 cathelicidin-like peptide in bacterial cells by intein-mediated system. Protein Expr Purif 2005; 39: 160-8.
39. Morin KM, Arcidiacono S, Beckwitt R et al. Recombinant expression of indolicidin concatamers in Escherichia coli. Appl Microbiol Biotechnol 2006; 70: 698-704.
40. Ahmad I, Perkins WR, Lupan DM et al. Liposomal entrapment of the neutrophil-derived peptide indolicidin endows it with in vivo antifungal activity. Biochim Biophys Acta 1995; 1237: 109-14.
41. Risso A, Zanetti M, Gennaro R. Cytotoxicity and apoptosis mediated by two peptides of innate immunity. Cell Immunol 1998; 189: 107-15.
42. Xiao Y, Cai Y, Bommineni YR et al. Identification and functional characterization of three chicken cathelicidins with potent antimicrobial activity. J Biol Chem 2006; 281: 2858-67.
43. Bowdish DM, Davidson DJ, Scott MG et al. Immunomodulatory activities of small host defense peptides. Antimicrob Agents Chemother 2005; 49: 1727-32.
44. Steinstraesser L, Tack BF, Waring AJ et al. Activity of novispirin G10 against Pseudomonas aeruginosa in vitro and in infected burns. Antimicrob Agents Chemother 2002; 46: 1837-44.